热门资讯> 正文

Checkpoint Therapeutics GAAP每股收益为-1.42美元

2025-03-28 20:32

Checkpoint Therapeutics(CKPT) 0

Checkpoint Therapeutics press release (NASDAQ:CKPT): FY GAAP EPS of -$1.42.
As of December 31, 2024, Checkpoint’s cash and cash equivalents totaled $6.6 million, compared to $4.9 million at December 31, 2023, an increase of $1.7 million. Subsequent to the end of the fiscal year, Checkpoint received approximately $38.1 million in cash proceeds through the exercise of existing warrants.

More on Checkpoint Therapeutics

Checkpoint Agrees To Sun Pharma Buyout: This Deal Suits Both Parties
Checkpoint Therapeutics: Pivoting From Approval To Gutsy Next Shot On Goal
India's Sun Pharma buys onco-derma firm Checkpoint Therapeutics for $355M
Seeking Alpha’s Quant Rating on Checkpoint Therapeutics
Historical earnings data for Checkpoint Therapeutics

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。